Datopotamab Deruxtecan, often abbreviated as DATO, represents an notable advancement in targeted cancer treatment. This innovative antibody-drug conjugate pairs the monoclonal immunoglobulin specifically targeting https://www.targetmol.com/compound/datopotamab